Danish pharmaceutical giant Novo Nordisk announced Monday the US Food and Drug Administration (FDA) had approved its popular GLP-1 anti-obesity drug Wegovy to be administered in pill form for weight loss.“With today’s approval of the Wegovy pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection,” Mike Doustdar, president and CEO of Novo Nordisk, said in a statement. For all the latest headlines, follow our Google News channel online or via the app.The FDA had already approved a pill to be used for treating diabetes, but the new development now allows doctors to prescribe the treatment for weight loss to adults with obesity or who are overweight with at least one weight-related comorbidity, such as a heart condition, the company said.The news was welcomed by the US Obesity Care Advocacy Network (OCAN), a nonprofit advocacy group for adults with obesity. “This development represents an important opportunity for